Related Experiment Videos
Plexiform neurofibromas.
1Division of Genetics, Department of Neurology, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. korf@hub.tch.harvard.edu
American Journal of Medical Genetics
|September 1, 1999
Summary
Plexiform neurofibromas, a complication of neurofibromatosis type 1, cause significant morbidity and can transform into malignant tumors. Current treatment focuses on surgical resection, with new therapies under investigation.
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- Plexiform neurofibromas are a frequent and severe complication of neurofibromatosis type 1 (NF1).
- These tumors cause disfigurement, functional impairment, and can be life-threatening.
- They carry a risk of malignant transformation into malignant peripheral nerve sheath tumors (MPNST).
Purpose of the Study:
- To review the current understanding and management of plexiform neurofibromas in NF1.
- To discuss the challenges in treating plexiform neurofibromas and MPNST.
- To highlight the potential for future medical treatments.
Main Methods:
- Review of existing literature on plexiform neurofibromas and MPNST.
- Discussion of diagnostic and follow-up strategies.
- Exploration of therapeutic options, including surgery and emerging treatments.
Main Results:
- Surgical resection remains the primary treatment for plexiform neurofibromas and MPNST.
- Diagnosis and timing of intervention are critical variables.
- Effective medical treatments are currently lacking, but research is advancing.
Conclusions:
- Management of plexiform neurofibromas requires careful consideration of identification, follow-up, and surgical indications.
- Malignant transformation to MPNST presents significant therapeutic challenges.
- Ongoing research into NF1 pathogenesis and tumor therapy offers hope for future clinical trials and improved treatments.